Plaintiff Judy K., a 59-year old resident of the State of Illinois, has added her complaint to the thousands accusing Daiichi Sankyo Inc., Forest Laboratories LLC and subsidiaries of both companies of negligence in the development and promotion of a hypertension medication which has led to severe Benicar gastrointestinal side effects.

Benicar Gastrointestinal Side Effects

Judy K., in her Benicar lawsuit dated May 11, 2017, is claiming personal injury to herself and economic loss resulting from health problems brought on by the use of Benicar.

Benicar is one of four olmetsartan products that have been accused of causing severe side effects including:

• Nausea
• Hemorrhoids
• Explosive Bowel Movements
• Rectal Bleeding
• Rectal Rash
• Anorexia
• Weight Loss
• Constipation
• Change of Appetite
• Repeat Urinary Tract Infections

Judy K. believes she has been wronged by the defendants in multiple ways as an outgrowth of medical problems like these.

As stated in her short-form complaint, she alleges that she has suffered immensely both physically and emotionally. She also claims significant financial liabilities because of the need for constant medical observation and resultant medical bills and inability to work during her medical monitoring period.

The plaintiff also believes the psychological damage coming out of her use of this olmetsartan product has limited her ability to earn income like she did before the onset of Benicar gastrointestinal side effects.

The plaintiff brings 15 counts against the defendants in her complaint, including violation of the consumer protection laws of the state of Illinois. She seeks an award of punitive and compensatory damages from the court, plus any other relief the court deems fair for the degree of her suffering from the alleged negligence of defendants.

The Benicar MDL

Judy K.’s short-form complaint is filed in the Benicar multidistrict litigation, or MDL, against Daiichi Sankyo and Forest Laboratories. This consolidation of Benicar lawsuits has been pending in a New Jersey federal court for about two years.

According to the plaintiffs’ master complaint for this MDL, Daiichi Sankyo and Forest Laboratories knew or should have known about the dangers associated with their products prior to placing it on the market.

Benicar was approved for the commercial marketplace in the United States as early as 2002.  It was made, marketed, distributed, and sold for the treatment of high-blood pressure or hypertension.

The defendants purportedly made a huge investment on Benicar’s marketing and promotion, exceeding $1 billion between 2002 and 2008.

The target market for such promotion is the 73 million people over 20 years of age that suffer from high-blood pressure in the United States alone. The marketing campaign also addressed prescribing physicians who would treat this patient group.

Judy K. and other plaintiffs in the MDL accuse the defendants of not doing proper safety tests and hiding information regarding potential and real risks while marketing and promoting the drug.

She and other plaintiffs believe that the Benicar gastrointestinal side effects they suffered could have been prevented if the leadership of the companies had cared for anything save short-term profit.